Drugs / Belotecan
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01784107 | Jul 2011 → Jul 2018 | small cell lung carcinoma | Gachon University Gil Medical Center | Unknown | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT01497873 | Sep 2010 → Dec 2017 | small cell lung carcinoma | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 2 | NCT01022671 | Sep 2009 → Feb 2010 | non-small cell lung carcinoma | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 2 | NCT00754858 | Oct 2008 → May 2010 | small cell lung carcinoma | Yonsei University | Completed | No outcome recorded |
| Phase 2 | NCT00430144 | Jan 2007 → Aug 2009 | cervical cancer | Sokbom Kang | Completed | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT00826644 | Jan 2009 → Feb 2013 | small cell carcinoma | Chonnam National University Hospital | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01630018 Comparator | Jan 2011 → Jun 2014 | malignant epithelial tumor of ovary | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-11-25 | Chong Kun Dang Pharmaceutical | Results 종근당, ‘캄토벨’ 후기 2상 임상 논문 ‘영국암저널’ 게재 ckdpharm.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-11-25 | Chong Kun Dang Pharmaceutical | 종근당, ‘캄토벨’ 후기 2상 임상 논문 ‘영국암저널’ 게재 ckdpharm.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Belotecan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00826644 ↗ |
| Known as | Belotecan hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL2111084 ↗ |
| Known as | belotecan hydrochloride | “Drug: belotecan hydrochloride” NCT00754858 ↗ |
| Known as | Camtobell inj. | “A phase II study is conducted to determine the efficacy and safety of a single agent Camtobell inj.(belotecan) on a weekly schedule in locally advanced or metastatic non-small...” NCT01022671 ↗ |
| Known as | CKD-602 | “Belotecan (Camtobell, CKD-602, Chong Kun Dang Pharm., Korea) is a new camptothecin derivative, that exhibits anticancer effects by inhibiting topoisomerase I.” NCT00826644 ↗1“Phase II study of belotecan (CKD 602) as a single agent in patients with recurrent or progressive carcinoma of uterine cervix.” PMID 21355002 ↗ Feb 2011 |
| Action | Inhibit | “belotecan (CKD 602), a topoisomerase I inhibitor” PMID 21355002 ↗ Feb 20111“DNA topoisomerase I inhibitor” CHEMBL2111084 ↗ |
| Modality | Small molecule | “Belotecan (Camtobell, CKD-602, Chong Kun Dang Pharm., Korea) is a new camptothecin derivative, that exhibits anticancer effects by inhibiting topoisomerase I.” NCT00826644 ↗ |
| Route | Intravenous | “belotecan hydrochloride IV on days 2-4” NCT00754858 ↗ |
| Target | TOP1 | “DNA topoisomerase I inhibitor” CHEMBL2111084 ↗ |